Completed PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT02960893

Trial in Adult Participants With Spinocerebellar Ataxia (SCA)

A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia

Sponsor: Biohaven Pharmaceuticals, Inc.

Conditions Spinocerebellar Ataxia Genotype Type 1 Spinocerebellar Ataxia Genotype Type 10 Spinocerebellar Ataxia Genotype Type 2 Spinocerebellar Ataxia Genotype Type 3 Spinocerebellar Ataxia Genotype Type 6 Spinocerebellar Ataxia Genotype Type 7 Spinocerebellar Ataxia Genotype Type 8 Spinocerebellar Ataxias

Interventions Placebo Troriluzole

Updated 23 times since 2017 Last updated: Sep 19, 2025 Started: Dec 15, 2016 Primary completion: Aug 18, 2017 Completion: Sep 20, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Spinocerebellar Ataxia Genotype Type 1 and Spinocerebellar Ataxia Genotype Type 10, this trial is completed. The trial is conducted by Biohaven Pharmaceuticals, Inc. and has accumulated 23 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

23 versions recorded

Nov 2025 — Present [monthly]

Completed PHASE2/PHASE3
Feb 2025 — Nov 2025 [monthly]

Completed PHASE2/PHASE3
Nov 2024 — Feb 2025 [monthly]

Completed PHASE2/PHASE3

Status: Active Not Recruiting → Completed
Sep 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3

▶ Show 18 earlier versions

May 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2_PHASE3
May 2023 — May 2024 [monthly]

Active Not Recruiting PHASE2_PHASE3
May 2022 — May 2023 [monthly]

Active Not Recruiting PHASE2_PHASE3
May 2021 — May 2022 [monthly]

Active Not Recruiting PHASE2_PHASE3
Jan 2021 — May 2021 [monthly]

Active Not Recruiting PHASE2_PHASE3
Sep 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2_PHASE3
Jun 2020 — Sep 2020 [monthly]

Active Not Recruiting PHASE2_PHASE3
Oct 2019 — Jun 2020 [monthly]

Active Not Recruiting PHASE2_PHASE3
Sep 2019 — Oct 2019 [monthly]

Active Not Recruiting PHASE2_PHASE3
Sep 2018 — Sep 2019 [monthly]

Active Not Recruiting PHASE2_PHASE3
Aug 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE2_PHASE3
Jul 2018 — Aug 2018 [monthly]

Active Not Recruiting PHASE2_PHASE3
Jun 2018 — Jul 2018 [monthly]

Active Not Recruiting PHASE2_PHASE3
Sep 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2_PHASE3
Jul 2017 — Sep 2017 [monthly]

Active Not Recruiting PHASE2_PHASE3

Status: Recruiting → Active Not Recruiting
May 2017 — Jul 2017 [monthly]

Recruiting PHASE2_PHASE3
Feb 2017 — May 2017 [monthly]

Recruiting PHASE2_PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2_PHASE3

First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biohaven Pharmaceuticals, Inc.

Data source: Biohaven Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Baltimore, United States , Boston, United States , Chicago, United States , Dallas, United States , Denver, United States , Gainesville, United States , Houston, United States , Long Beach, United States and 6 more locations